Document is current
Any future updates will be listed below
-
Authors
Vanderhaeghe, Silke
Prerad, Jovan
Tharkeshwar, Arun Kumar
Goethals, Elien
Vints, Katlijn
Beckers, Jimmy
Scheveneels, Wendy
Debroux, Eveline
Princen, Katrien
Van Damme, Philip
Fivaz, Marc
Griffioen, Gerard
Van Den Bosch, Ludo
-
Funding
Funding for this research was provided by:
VLAIO Baekeland mandate (HBC.2019.2575)
Flanders Innovation & Entrepreneurship (030383)
- License Information
-
More Information
Article History
Received: 14 August 2024
Accepted: 23 September 2024
First Online: 10 October 2024
Declarations
:
: Not applicable.
: PVD has served in advisory boards for Biogen, CSL Behring (King of Prussia, US), Alexion Pharmaceuticals (Boston, Us), Ferrer (Barcelona, Spain), QurAlis (Cambridge, UK), Cytokinetics (South San Francisco, US), Argenx (Boston, US), UCB (Brussels, Belgium), Muna Therapeutics, Alector (South San Francisco, US), Augustine Therapeutics (Leuven, Belgium), VectorY (Amsterdam, Netherlands), Zambon (Bresso, Italy), Amylyx (Cambridge, UK) (paid to institution). P.V.D. has received speaker fees from Biogen and Amylyx (paid to institution). PVD is supported by the E. von Behring Chair for Neuromuscular and Neurodegenerative Disorders (from CSL Behring, paid to institution). ED, KP and MF own reMYND warrants. GG is a consultant for reMYND and owns reMYND warrants and shares. LVDB is head of the Scientific Advisory Board of Augustine Therapeutics and is part of the Investment Advisory Board of Droia Ventures (Meise, Belgium). LVDB is a scientific founder of Augustine Therapeutics.
